Richard Malamut Net Worth

Richard Malamut biography

Richard Malamut serves as Executive Vice President and Chief Medical Officer of the Company. Dr. Malamut has served as our Chief Medical Officer since April 2019. Prior to joining us, Dr. Malamut served as Chief Medical Officer, Head of Research and Development and Senior Vice President at Braeburn Pharmaceuticals from June 2018 to January 2019; Chief Medical Officer at Avanir Pharmaceuticals from November 2016 to June 2018; and Senior Vice President of Global Clinical Development at Teva Pharmaceuticals Industries Ltd from March 2013 to November 2016. Dr. Malamut also previously held roles of increasing responsibility at Bristol-Myers Squibb and AstraZeneca focusing on early clinical development and translational medicine in neurology and analgesia. Dr. Malamut holds a medical degree from Hahnemann University in June 1985 and a B.S. in Biology from Trinity College in May 1981. Dr. Malamut worked as a board-certified academic and clinical neurologist for 17 years and has more than 50 publications in the fields of pain medicine, neuromuscular disease, autonomic disease and neurodegenerative disease.

What is the salary of Richard Malamut?

As the Executive Vice President and Chief Medical Officer of Collegium Pharmaceutical Inc, the total compensation of Richard Malamut at Collegium Pharmaceutical Inc is $1,922,820. There are 2 executives at Collegium Pharmaceutical Inc getting paid more, with Joseph Ciaffoni having the highest compensation of $4,032,630.

How old is Richard Malamut?

Richard Malamut is 60, he's been the Executive Vice President and Chief Medical Officer of Collegium Pharmaceutical Inc since 2019. There are 7 older and 11 younger executives at Collegium Pharmaceutical Inc. The oldest executive at Collegium Pharmaceutical Inc is John Fallon, 72, who is the Independent Director.

What's Richard Malamut's mailing address?

Richard's mailing address filed with the SEC is C/O COLLEGIUM PHARMACEUTICAL, INC., 100 TECHNOLOGY CENTER DRIVE, STOUGHTON, MA, 02072.

Insiders trading at Collegium Pharmaceutical Inc

Over the last 10 years, insiders at Collegium Pharmaceutical Inc have traded over $80,399,308 worth of Collegium Pharmaceutical Inc stock and bought 1,112,375 units worth $13,316,951 . The most active insiders traders include Group Holdings (Sbs) Adviso..., John Gordon Freund, eDavid Hirsch. On average, Collegium Pharmaceutical Inc executives and independent directors trade stock every 35 days with the average trade being worth of $2,130,406. The most recent stock trade was executed by Shirley R. Kuhlmann on 5 September 2024, trading 20,225 units of COLL stock currently worth $773,809.

What does Collegium Pharmaceutical Inc do?

collegium pharmaceutical, inc. is a specialty pharmaceutical company developing and planning to commercialize next generation, abuse-deterrent products for the treatment of patients suffering from chronic pain and other diseases. with a substantial number of patients suffering from chronic pain, collegium is committed to developing and commercializing a portfolio of products that address the growing problems associated with non-medical use, abuse and misuse of prescription products by leveraging the company’s proprietary deterx® technology platform. deterx technology can be used with drugs that are commonly abused such as opioids and amphetamines, as well as drugs that have a narrow therapeutic index that would benefit from protection against misuse such as breaking, crushing, grinding, or dissolving the product. the deterx technology platform is covered by u.s. and international patents and patent applications. collegium’s lead product candidate, xtampza er™, is an abuse-deterrent, ex

Collegium Pharmaceutical Inc executives and stock owners

Collegium Pharmaceutical Inc executives and other stock owners filed with the SEC include:

• Joseph Ciaffoni,
  President, Chief Executive Officer, Director
• Scott Dreyer,
  Executive Vice President, Chief Commercial Officer
• Richard Malamut,
  Executive Vice President and Chief Medical Officer
• Paul Brannelly,
  Chief Financial Officer, Executive Vice President
• Shirley Kuhlmann,
  Executive Vice President, General Counsel, Secretary
• Alison Fleming,
  Executive Vice President, Chief Technology Officer
• Joseph J. Ciaffoni,
  Pres, CEO & Director
• Shirley R. Kuhlmann,
  Exec. VP, Gen. Counsel & Sec.
• Dr. Richard Malamut,
  Exec. VP & Chief Medical Officer
• Michael Heffernan,
  Chairman of the Board
• Gino Santini,
  Lead Independent Director
• Garen Bohlin,
  Independent Director
• John Fallon,
  Independent Director
• Theodore Schroeder,
  Independent Director
• John Freund,
  Independent Director
• Gwen Melincoff,
  Independent Director
• Michael Thomas Heffernan B.S. Pharm, R.Ph.,
  Co-Founder & Chairman
• Michael Thomas Heffernan,
  Co-Founder & Chairman
• Rita Balice-Gordon,
  Director
• Scott Sudduth,
  Head of Technical Operations
• Marlo Manning,
  Head of HR
• Scott Dreyer,
  Exec. VP & Chief Commercial Officer
• Colleen Tupper,
  Exec. VP & CFO
• Jack Maroney,
  VP of Sales
• Bart J. Dunn,
  Exec. VP of Strategy & Corp. Devel.
• Alex Dasalla,
  Head of Investor Relations
• Barry S Duke,
  See remarks
• Eran Nadav,
  Director
• David Hirsch,
  Director
• Yasunori Kaneko,
  10% owner
• Venture Partners V Lp Skyli...,
  
• Capital Partners, Llc Tamme...,
  
• Thomas B Smith,
  EVP and Chief Medical Officer
• Colleen Tupper,
  EVP & Chief Financial Officer
• Patrick J Heron,
  Director
• Capital Partners, Llc Longi...,
  
• Healthcare Vi, L.P.Fhm Vi, ...,
  
• Group Holdings (Sbs) Adviso...,
  
• Venture Partners V Lp Skyli...,
  
• Neil F. Mc Farlane,
  Director